Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech announced that Chief Medical Officer Thomas Heineman will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference on April 20, 2023. The event starts at 9:00 a.m. ET, and a live webcast will be accessible to registered attendees. Company management will also engage in virtual one-on-one investor meetings throughout the conference. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent designed to enhance anti-cancer immune responses for various cancers. The company is advancing clinical trials to evaluate pelareorep in combination with other treatments for conditions like metastatic breast and pancreatic cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2023, at 8:30 a.m. ET to discuss the first quarter financial results and provide a corporate update. The call can be accessed via toll-free numbers for North America and international callers, and a replay will be available for one week post-event. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers by inducing anti-cancer immune responses. The company is exploring combinations of pelareorep with checkpoint inhibitors and other oncology treatments, particularly targeting metastatic breast cancer and pancreatic cancer. For further details, visit Oncolytics Biotech's website.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released its annual general meeting notice, which will take place virtually on May 9, 2023, at 4:00 p.m. Toronto time. Shareholders can view the management information circular on the company's website. Proxy solicitation is being handled by Laurel Hill Advisory Group, with a fee of $35,000 plus expenses. Shareholders are urged to vote before the 4:00 p.m. deadline on May 5, 2023. The board of directors recommends voting for all nominees and resolutions. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at enhancing anti-cancer immune responses, with ongoing clinical trials.
On March 28, 2023, Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that Dr. Matt Coffey, President and CEO, will participate in the 'Novel Mechanisms with Important Readouts' panel at Cantor Fitzgerald's The Future of Oncology Virtual Symposium from April 3-5, 2023. The panel is scheduled for April 3 at 11:00 a.m. ET. A live webcast and archived replay will be accessible to registered attendees. Oncolytics is advancing clinical trials for its immunotherapeutic agent, pelareorep, which enhances anti-cancer immune responses and targets various cancers, including metastatic breast and pancreatic cancer.
Oncolytics Biotech announced operational highlights and financial results for Q4 and full year 2022, emphasizing progress in its pancreatic and breast cancer programs. Notably, the phase 1/2 GOBLET trial showed a 69% objective response rate in advanced pancreatic cancer, leading to FDA Fast Track designation. The BRACELET-1 trial in metastatic breast cancer is on track for data readout in Q2 2023. As of December 31, 2022, the company reported $32.1 million in cash, providing a runway through anticipated milestones. The net loss for Q4 2022 was $8.6 million, and for the full year, it was $24.8 million, reflecting a decrease in losses compared to 2021.
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call and webcast to discuss its fourth quarter and full year 2022 financial results, scheduled for March 3, 2023, at 8:30 a.m. ET. The call will cover corporate updates and financial insights regarding the company’s lead immunotherapeutic agent, pelareorep, which is in trials for treating various cancers. The company is advancing towards registration studies in metastatic breast cancer and pancreatic cancer while evaluating pelareorep in combination with immune checkpoint inhibitors.
Oncolytics Biotech's partner Adlai Nortye presented interim results from a bridging clinical trial evaluating pelareorep-paclitaxel therapy for advanced HR+/HER2- breast cancer in Chinese patients. Out of 14 evaluable patients, 93% achieved disease control, with 86% showing tumor shrinkage. The median progression-free survival (PFS) was reported at 9.1 months. The combination therapy was well tolerated with no serious adverse events. Upcoming data from the ongoing BRACELET-1 trial are anticipated to further support pelareorep's development towards regulatory approval.
Oncolytics Biotech (NASDAQ: ONCY) announced FDA Fast Track designation for pelareorep combined with atezolizumab, gemcitabine, and nab-paclitaxel to treat advanced pancreatic ductal adenocarcinoma (PDAC). This designation follows a reported 69% objective response rate from their phase 1/2 GOBLET study, significantly higher than the historical average of ~25%. Fast Track status enables more frequent communication with the FDA, potentially leading to Accelerated Approval and Priority Review. Oncolytics is focused on pivotal trials for its core programs in breast and pancreatic cancer.
Oncolytics Biotech announced promising results from the phase 1/2 GOBLET study, demonstrating a 69% objective response rate (ORR) for first-line treatment of advanced pancreatic cancer, significantly outperforming the historical average of 25%. In total, 85% of patients showed a clinical benefit, with plans to advance to a pivotal study. The interim findings will be discussed in a key opinion leader webinar on November 14, 2022. The GOBLET study highlights the potential of pelareorep when combined with atezolizumab and chemotherapy, showing encouraging results for pancreatic cancer treatment.
Oncolytics Biotech reported significant interim data from its GOBLET trial, revealing a 70% objective response rate (ORR) for pancreatic cancer, nearly triple the historical average of 25%. The company holds $32.4 million in cash, projected to fund operations through 2023. They plan further studies for both pancreatic and breast cancer treatments, aiming for pivotal trials, with impactful results expected from their BRACELET-1 trial in early 2023. Despite a net loss of $4.4 million for Q3 2022, losses are down from $4.9 million during the same period last year.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
